AZD-4877

AZD-4877 is a synthetic small molecule inhibitor of kinesin spindle protein (KSP, also known as Eg5 or KIF11), developed by AstraZeneca for the treatment of various cancers. By selectively inhibiting KSP, which is essential for mitotic spindle formation and proper segregation of sister chromatids during mitosis, AZD-4877 disrupts cell division in actively dividing tumor cells. This leads to mitotic arrest and subsequent cell death. Unlike tubulin-targeting agents, KSP inhibitors like AZD‑4877 may have a lower risk of causing peripheral neuropathy because KSP is not involved in postmitotic processes such as neuronal transport. The drug has been investigated in phase I/II clinical trials for hematological malignancies (including acute myeloid leukemia and lymphoma) and solid tumors (such as bladder cancer), but development was discontinued after phase II due to lack of sufficient efficacy[1][3][5][6][8].

Other names

1176760-49-8UNII-19ORU63E06UNII19ORU63E06UNII 19ORU63E06